-DOCSTART- -X- O
The -X- _ O
ubiquitin-proteasome -X- _ O
system -X- _ O
( -X- _ O
UPS -X- _ O
) -X- _ O
is -X- _ O
the -X- _ O
primary -X- _ O
mechanism -X- _ O
by -X- _ O
which -X- _ O
intracellular -X- _ O
proteins -X- _ O
, -X- _ O
transcription -X- _ O
factors -X- _ O
, -X- _ O
and -X- _ O
many -X- _ O
proteotoxic -X- _ O
proteins -X- _ O
with -X- _ O
aggregation-prone -X- _ O
structures -X- _ O
are -X- _ O
degraded. -X- _ O
The -X- _ O
UPS -X- _ O
is -X- _ O
reportedly -X- _ O
downregulated -X- _ O
in -X- _ O
various -X- _ O
neurodegenerative -X- _ O
disorders -X- _ O
, -X- _ O
with -X- _ O
increased -X- _ O
proteasome -X- _ O
activity -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
beneficial -X- _ O
in -X- _ O
many -X- _ O
related -X- _ O
disease -X- _ O
models. -X- _ O
Proteasomes -X- _ O
function -X- _ O
under -X- _ O
tonic -X- _ O
inhibitory -X- _ O
conditions -X- _ O
, -X- _ O
possibly -X- _ O
via -X- _ O
the -X- _ O
ubiquitin -X- _ O
chain-trimming -X- _ O
function -X- _ O
of -X- _ O
USP14 -X- _ O
, -X- _ O
a -X- _ O
proteasome-associated -X- _ O
deubiquitinating -X- _ O
enzyme -X- _ O
( -X- _ O
DUB -X- _ O
) -X- _ O
. -X- _ O
We -X- _ O
identified -X- _ O
three -X- _ O
specific -X- _ O
RNA -X- _ B-Intervention
aptamers -X- _ I-Intervention
of -X- _ I-Intervention
USP14 -X- _ I-Intervention
( -X- _ I-Intervention
USP14-1 -X- _ I-Intervention
, -X- _ I-Intervention
USP14-2 -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
USP14-3 -X- _ I-Intervention
) -X- _ I-Intervention
that -X- _ O
inhibited -X- _ O
its -X- _ O
deubiquitinating -X- _ O
activity. -X- _ O
The -X- _ O
nucleotide -X- _ O
sequences -X- _ O
of -X- _ O
these -X- _ O
non-cytotoxic -X- _ O
USP14 -X- _ O
aptamers -X- _ O
contained -X- _ O
conserved -X- _ O
GGAGG -X- _ O
motifs -X- _ O
, -X- _ O
with -X- _ O
G-rich -X- _ O
regions -X- _ O
upstream -X- _ O
, -X- _ O
and -X- _ O
similar -X- _ O
secondary -X- _ O
structures. -X- _ O
They -X- _ O
efficiently -X- _ B-Outcome
elevated -X- _ I-Outcome
proteasomal -X- _ I-Outcome
activity -X- _ I-Outcome
, -X- _ O
as -X- _ O
determined -X- _ O
by -X- _ O
the -X- _ O
increased -X- _ B-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
small -X- _ I-Outcome
fluorogenic -X- _ I-Outcome
peptide -X- _ I-Outcome
substrates -X- _ I-Outcome
and -X- _ I-Outcome
physiological -X- _ I-Outcome
polyubiquitinated -X- _ I-Outcome
Sic1 -X- _ I-Outcome
proteins. -X- _ I-Outcome
Additionally -X- _ O
, -X- _ O
proteasomal -X- _ B-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
tau -X- _ I-Outcome
proteins -X- _ I-Outcome
was -X- _ I-Outcome
facilitated -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
presence -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
UPS14 -X- _ I-Outcome
aptamers -X- _ I-Outcome
in -X- _ I-Outcome
vitro. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
these -X- _ O
novel -X- _ O
inhibitory -X- _ O
UPS14 -X- _ O
aptamers -X- _ O
can -X- _ O
be -X- _ O
used -X- _ O
to -X- _ O
enhance -X- _ O
proteasome -X- _ O
activity -X- _ O
, -X- _ O
and -X- _ O
to -X- _ O
facilitate -X- _ O
the -X- _ O
degradation -X- _ O
of -X- _ O
proteotoxic -X- _ O
proteins -X- _ O
, -X- _ O
thereby -X- _ O
protecting -X- _ O
cells -X- _ O
from -X- _ O
various -X- _ O
neurodegenerative -X- _ O
stressors -X- _ O
. -X- _ O

